Richwood Investment Advisors LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Richwood Investment Advisors LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 12.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,648 shares of the company’s stock after buying an additional 396 shares during the quarter. Richwood Investment Advisors LLC’s holdings in Johnson & Johnson were worth $528,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Swedbank AB raised its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares during the period. Principal Financial Group Inc. grew its stake in Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank grew its stake in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after purchasing an additional 202 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in Johnson & Johnson during the 3rd quarter worth $365,000. Finally, Eagle Asset Management Inc. grew its stake in Johnson & Johnson by 22.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 57,612 shares of the company’s stock worth $8,957,000 after purchasing an additional 10,439 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $163.40 on Friday. The business’s 50-day moving average is $156.99 and its two-hundred day moving average is $156.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market capitalization of $393.76 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.